CRISPR 2.0?

A pioneer of the gene-editing technique discovers a protein that could improve its accuracy.

Written byJef Akst
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Crystal structure of a Cas9 in complex with an RNA guide and a stretch of target DNAWIKIMEDIA, H. NISHIMASU ET AL.Searching bacteria for an alternative to Cas9, the enzyme used in the CRIPSR system to cut DNA at a site specified by RNA guides, synthetic biologist Feng Zhang of the Broad Institute in Cambridge, Massachusetts, and his colleagues discovered a protein called Cpf1 in some bacteria that use CRISPR for viral defense. Taking a closer look at Cpf1 from 16 microbial species, the research team identified two that could cut human DNA, they reported last week (September 25) in Cell.

“It’s a noteworthy addition to the biology [of CRISPR] and a valuable addition to the tool box,” North Carolina State University molecular biologist Rodolphe Barrangou, who did not participate in the research, told Science.

Important differences exist between Cpf1 and Cas9. Cas9 relies on two RNA molecules to specify the DNA to be cut, while Cpf1 only requires one, for instance. And the nature of the cut is also different: Cas9 cuts both DNA strands at the same location, while Cpf1 snips DNA such that there are short, single-stranded pieces on either side of the cut. “The sticky ends carry information that can direct the insertion of the DNA,” Zhang told Nature. “It makes the insertion much more controllable.”

The sticky ends could also improve ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies